
PT 141 Peptide 10mg
High-purity research peptide vial
$45.00
Out of stock
Benefits of PT-141 (Bremelanotide)
Enhanced Sexual Function: Stimulates melanocortin receptors to improve libido, sexual arousal, and erectile function in men and women.
Treatment for Sexual Dysfunction: Effective for erectile dysfunction and female sexual arousal disorder, offering an alternative to traditional therapies.
Mood and Motivation Boost: May enhance mood and motivation by acting on the central nervous system, improving overall well-being.
Rapid Onset: Produces effects within hours of administration, providing quick results for sexual performance.
Non-Hormonal Action: Works independently of hormonal pathways, making it suitable for individuals with hormonal imbalances.
Potential Weight Management: May reduce appetite and support fat loss through melanocortin receptor activation.
Improved Intimacy: Enhances emotional and physical connection by increasing sexual desire and satisfaction.
Neuroprotective Potential: Early research suggests possible benefits for brain health via melanocortin pathways.
Trusted source for high-quality research peptides.
Support
info@peptidea.net
© 2025. All rights reserved.
Peptidea is a supplier of high-purity peptides, proteins, and amino acid derivatives intended solely for research and development purposes. Our products are not for human consumption. In research settings, peptides are often studied for their potential applications in areas such as weight management, anti-aging, and energy enhancement. All products are provided as lyophilized powders, requiring reconstitution with bacteriostatic water for research use. The statements on this website have not been evaluated by the US Food and Drug Administration, and our products are not intended to diagnose, treat, cure, or prevent any disease. Peptidea is a chemical supplier and is neither a compounding pharmacy nor a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under Section 503B of the same Act.